MECHANISM OF DEATH IN HEART-FAILURE - THE VASODILATOR-HEART FAILURE TRIALS

被引:0
作者
GOLDMAN, S
JOHNSON, G
COHN, JN
CINTRON, G
SMITH, R
FRANCIS, G
机构
[1] VET AFFAIRS MED CTR, CTR COOPERAT STUDIES COORDINATING, West Haven, CT USA
[2] VET AFFAIRS MED CTR, CTR COOPERAT STUDIES COORDINATING, MINNEAPOLIS, MN USA
[3] VET AFFAIRS MED CTR, CTR COOPERAT STUDIES, TAMPA, FL USA
[4] VET AFFAIRS MED CTR, CTR COOPERAT STUDIES COORDINATING, NASHVILLE, TN USA
关键词
CLINICAL TRIALS; HEART FAILURE; MORBIDITY; MORTALITY; SUDDEN DEATH;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. The Vasodilator-Heart Failure Trial (V-HeFT) data base provides information on the mechanism of death of male veterans entered into two trials that evaluated the effect of vasodilator therapy on survival in heart failure. Methods and Results. Men aged 18-75 years with heart failure were recruited at 13 Department of Veterans Affairs Medical Centers. In V-HeFT I, 283 of 642 patients (44%) died during follow-up (average, 2.3 years), and in V-HeFT II, 285 of 804 randomized patients (35.5%) died during follow-up (average, 2.5 years). Mechanism of death was established centrally using a standardized classification. In V-HeFT I, 124 of the 283 deaths (43.8%) were sudden with no worsening of symptoms; in V-HeFT II, 104 of the 285 deaths (36.5%) were sudden. An average of 31.5% of the deaths (31.4% and 31.6%, respectively) in the two trials was due to pump failure. The proportion of sudden deaths that occurred without worsening of symptoms was similar in patients with and without ischemic heart failure. Sudden deaths tended to occur earlier and pump failure deaths later in both V-HeFT studies. There was a trend for a lower percentage of cardiac deaths from pump failure and a higher percentage from sudden death in subgroups with higher peak exercise oxygen consumption (VO2), higher ejection fraction, and lower plasma norepinephrine levels. The proportion of deaths that occurred suddenly was similar in placebo, prazosin, and hydralazine plus isosorbide dinitrate treatment groups but was significantly lower in the enalapril treatment group. In V-HeFT I, measures of cardiac function and VO2 predicted pump failure death and sudden death. In V-HeFT II, VO2 and cardiothoracic ratio were independent predictors of all-cause deaths and pump failure deaths; only ejection fraction was an independent predictor of both pump failure and sudden death. Conclusion. Although mechanistically distinct terminal events can be identified in patients with heart failure and physiological measurements can provide some insight into the risk of these disparate events, sudden death and pump failure death both appear largely to be linked to the severity of cardiac dysfunction and symptoms. Strategies to identify individuals for selective preventive therapy are not yet practical.
引用
收藏
页码:24 / 31
页数:8
相关论文
共 50 条
  • [41] Death in Heart Failure A Community Perspective
    Henkel, Danielle M.
    Redfield, Margaret A.
    Weston, Susan A.
    Gerber, Yariv
    Roger, Veronique L.
    CIRCULATION-HEART FAILURE, 2008, 1 (02) : 91 - 97
  • [42] Sudden death prophylaxis in heart failure
    Rosanio, Salvatore
    Schwarz, Ernst R.
    Vitarelli, Antonio
    Zarraga, Ignatius Gerardo E.
    Kunapuli, Sanjay
    Ware, David L.
    Birnbaum, Yochai
    Tuero, Enrique
    Uretsky, Barry F.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2007, 119 (03) : 291 - 296
  • [43] Obesity, heart failure and sudden death
    Contaldo, F
    Pasanisi, F
    Finelli, C
    de Simone, G
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2002, 12 (04) : 190 - 197
  • [44] Trends in prevalence of comorbidities in heart failure clinical trials
    Khan, Muhammad Shahzeb
    Tahhan, Ayman Samman
    Vaduganathan, Muthiah
    Greene, Stephen J.
    Alrohaibani, Alaaeddin
    Anker, Stefan D.
    Vardeny, Orly
    Fonarow, Gregg C.
    Butler, Javed
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (06) : 1032 - 1042
  • [45] Arrhythmias and sudden death in heart failure
    Stevenson, WG
    Sweeney, MO
    JAPANESE CIRCULATION JOURNAL-ENGLISH EDITION, 1997, 61 (09): : 727 - 740
  • [46] Postponement of Death by Pharmacological Heart Failure Treatment: A Meta-Analysis of Randomized Clinical Trials
    Hansen, Morten Rix
    Hrobjartsson, Asbjorn
    Videbaek, Lars
    Ennis, Zandra Nymand
    Pareek, Manan
    Paulsen, Niels Herluf
    Broe, Martin
    Olesen, Morten
    Pottegard, Anton
    Damkier, Per
    Hallas, Jesper
    AMERICAN JOURNAL OF MEDICINE, 2020, 133 (06) : E280 - E289
  • [47] FUNCTIONAL-CAPACITY IN HEART-FAILURE - COMPARISON OF METHODS FOR ASSESSMENT AND THEIR RELATION TO OTHER INDEXES OF HEART-FAILURE
    SMITH, RF
    JOHNSON, G
    ZIESCHE, S
    BHAT, G
    BLANKENSHIP, K
    COHN, JN
    CIRCULATION, 1993, 87 (06) : 88 - 93
  • [48] Mode of Death in Patients With Heart Failure and Reduced vs. Preserved Ejection Fraction - Report From the Registry of Hospitalized Heart Failure Patients
    Hamaguchi, Sanae
    Kinugawa, Shintaro
    Sobirin, Mochamad Ali
    Goto, Daisuke
    Tsuchihashi-Makaya, Miyuki
    Yamada, Satoshi
    Yokoshiki, Hisashi
    Tsutsui, Hiroyuki
    CIRCULATION JOURNAL, 2012, 76 (07) : 1662 - 1669
  • [49] Agents with vasodilator properties in acute heart failure
    Singh, Abhishek
    Laribi, Said
    Teerlink, John R.
    Mebazaa, Alexandre
    EUROPEAN HEART JOURNAL, 2017, 38 (05) : 317 - +
  • [50] ASSURANCE AGAINST DRUG-INDUCED DEATH IN PATIENTS WITH HEART-FAILURE
    RECTOR, TS
    CARDIOVASCULAR DRUGS AND THERAPY, 1993, 7 (05) : 829 - 830